Sponsored by China Pharmaceutical Innovation and Research Development Association and the Food and Drug Administration of the United States, the China-US Cancer Experts' Roundtable concluded at Worldhotel Grand Dushulake Suzhou, SIP on July 6.

At the event, Chinese and US representatives from drug regulators, industrial associations and pharmaceutical enterprises exchanged information about the latest policies of the two countries on drug development and business, and shared their opinions on global trends of anticancer drugs.

Ding Lixin, deputy director of SIP Administrative Committee, gave an introduction to the strong development momentum of biomedicine businesses in SIP, inviting overseas medical experts and companies to launch their projects in the area.